Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not yet. He needs an ER approval and SunGen to move.
Company will focus on IR. Still huge revs and company will survive and thrive but not in IR space, which is massive. They tried doing what no other company could and looked good...until now.
Eugene has this one in the bag. Working behind the scenes I am sure, right Couch?
Thought it was interesting that they had 3 "options" to prove BE. Not a chance. Tails will be tucked on this one for a while.
Might want to revise this. It simply doesn't work.
CDC says opiate Rex's decreased almost 20% in 5 years:
http://www.cnn.com/2017/07/06/health/opioid-prescriptions-cdc/index.html
Kinda hurts the industry growth rates.
Sort of. He pays himself through these Mikah deals.
I also agree with the share price being much closer to all-time lows under Nasrat's tenure than the highs. Ouch!!
It makes me laugh. It's just sad the things people resort to for their benefit.
I believe he said "should", so falls under Safe Harbor. Hopefully will be within next couple of weeks.
Lol love the twisting and lies. Haha!
Oh no! Significantly closer to the bottom of the range than the top.
Well, he was CEO when it hit 0.97. Whoopsie!
Same to you! A big thanks for any and all veterans.
I have been hearing If this If that for years. You will soon come around to the reality of the situation soon enough.
The only "if" is if the CEO continues non-arms length transactions how long will he continue to last?
Haha! Buy all under 0.35!! Forget to mention that it will be closer to 0.02 than 0.97 for a loooong time.
Results are results. The company has potential, but I think management has done a terrible job the last 12 months.
We may have to wait for an update after next Valentine's Day dinner just to realize that he's been stood up.
He did before and the dialogue has since changed. He preciously said that the company could get to NASDAQ on the fundamentals alone. That was before the CRL, of course, and prior to the incessant dilution.
"We will see what happens" sounds like the usual solid plan.
These are never scheduled. Always an option on the table.
Good thing expectations were met and nailed down that hard shell Oxy ANDA "this" quarter.
If anything, this company is consistent.
Could simply be turnover.
Article: https://news.google.com/news/amp?caurl=http%3A%2F%2Fwww.cnn.com%2F2017%2F06%2F29%2Fhealth%2Fohio-overdose-proposal-trnd%2Findex.html#pt0-25903
Extremely sad of what the opiate situation is coming down to - raise taxes to support the medical assistance & crisis situation or simply stop sending help. Wow.
No BK is coming, but there will be plenty more dilution to cover all the excuses.
First he wants to validate they even really work so he is forcing additional studies.
Won't need to since it is posted multiple times each day.
Haha! Funny that an entire site is shut down to post an entry-level position.
Nasrat just forgot to insert the word "next" as in this next quarter.
Was that before or after dumping of shares?
That was one day. And what has it done since? Very sad.
How has the price increased since the cc? I see quite the opposite, as usual.
...Plus J shares
I will quote Nasrat from the last cc, "that was really disappointing."
I guess so. Sort of like an inverted ladder after the fall from 0.97.
Actually looks like lots of selling has taken place since the last conference call again. With self-dealing CEO is getting a payday regardless of stock price.
How have they been doing sequentially recently? Not climbing for sure.
Haha! It was one of the reasons. Didn't I hear Methadone contracted sales dropped significantly during the quarter? Good thing they didn't use the excuse of "shipping delays". Would have been the 3rd straight quarter.
How is that July 2016 slam dunk approval doing?
If it is a 5-bagged that assumes only a 20% annual growth rate. That would be a piss poor return for the risk involved here and I would be embarrassed if I was in management if that really was the outcome.